A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer

Clinical trial NCT04569747 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04569747
Sponsor: Dana-Farber Cancer Institute
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

HER2-positive Breast Cancer Invasive Carcinoma of the Breast Breast Cancer Node Negative Breast Cancer Micrometastasis Breast Cancer Hormone Receptor Positive Breast Cancer

Start date: 2021-01-11
Primary completion: 2026-03-23
Enrollment: 393

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.